The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Alterations in two oncogenic drivers: Impact of concurrent PIK3CA or AKT1 mutations in patients with oncogene-driven lung adenocarcinomas.
Juliana Eng
No relevant relationships to disclose
Matthew David Hellmann
No relevant relationships to disclose
Kaitlin Woo
No relevant relationships to disclose
Camelia S. Sima
No relevant relationships to disclose
Helena Alexandra Yu
No relevant relationships to disclose
Maria E. Arcila
No relevant relationships to disclose
Marc Ladanyi
No relevant relationships to disclose
Mark G. Kris
Consultant or Advisory Role - AstraZeneca; Exelixis; Novartis; Pfizer; Roche/Genentech
Research Funding - Boehringer Ingelheim; Pfizer; Puma Biotechnology
Alexander E. Drilon
No relevant relationships to disclose